TORONTO, Oct. 6 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today
announced that it has delivered a TLC-3000 prototype PDC light system to
University Health Network for the pre-clinical evaluation of Theralase's
patented oxygen independent photodynamic compounds (PDCs) in the destruction
of cancer, bacteria, viruses and fat cells.
